Basel Pharmacoepidemiology Unit, Hospital Pharmacy, University Hospital, Spitalstrasse 26, CH-4031 Basel, Switzerland.
Parkinsonism Relat Disord. 2010 Mar;16(3):186-90. doi: 10.1016/j.parkreldis.2009.11.005. Epub 2009 Nov 28.
Data from large population-based studies on the association between Parkinson disease (PD) and the risk of developing cancer are scarce. We compared the risk of developing incident cancer between patients with or without PD.
We conducted a population-based follow-up study and a nested case-control analysis using data from the UK-based General Practice Research Database. We included PD patients aged >or=40 years with a first PD diagnosis between 1994 and 2005, and a matched comparison group free of PD. We assessed cancer incidence rates and relative risk estimates (odds ratios [ORs] with 95% confidence intervals [CI]).
The risk of developing cancer overall was lower in PD patients as compared to patients without PD (crude incidence rate ratio 0.77, 95% CI 0.64-0.92). In the nested case-control analysis (adj. OR for all cancers 0.72, 95% CI 0.59-0.87) the risk reduction was strongest for smoking-related cancers (adj. OR 0.47, 95% CI 0.31-0.72). The adjusted OR for hematological malignancies was 0.32 (95% CI 0.14-0.74). Due to small numbers, ORs for other cancer entities did not reach statistical significance.
With the exception of melanoma, PD patients were less likely to develop cancer than individuals without PD in this large observational study.
关于帕金森病（PD）与癌症风险之间关联的大型基于人群的研究数据较为缺乏。我们比较了有和无 PD 的患者发生新发癌症的风险。
我们开展了一项基于人群的随访研究和一项嵌套病例对照分析，使用了来自英国普通实践研究数据库的数据。我们纳入了年龄≥40 岁、1994 年至 2005 年间首次被诊断为 PD 的 PD 患者，以及无 PD 的匹配对照组。我们评估了癌症发病率和相对风险估计值（比值比 [OR]及其 95%置信区间 [CI]）。
与无 PD 的患者相比，PD 患者总体发生癌症的风险较低（粗发病率比 0.77，95%CI 0.64-0.92）。在嵌套病例对照分析中（所有癌症的调整 OR 0.72，95%CI 0.59-0.87），与吸烟相关的癌症的风险降低最为显著（调整 OR 0.47，95%CI 0.31-0.72）。血液恶性肿瘤的调整 OR 为 0.32（95%CI 0.14-0.74）。由于数量较少，其他癌症实体的 OR 未达到统计学意义。
在这项大型观察性研究中，除黑色素瘤外，PD 患者发生癌症的风险低于无 PD 的个体。
